» Articles » PMID: 38568722

Data-Driven Identification of Factors That Influence the Quality of Adverse Event Reports: 15-Year Interpretable Machine Learning and Time-Series Analyses of VigiBase and QUEST

Overview
Journal JMIR Med Inform
Publisher JMIR Publications
Date 2024 Apr 3
PMID 38568722
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The completeness of adverse event (AE) reports, crucial for assessing putative causal relationships, is measured using the vigiGrade completeness score in VigiBase, the World Health Organization global database of reported potential AEs. Malaysian reports have surpassed the global average score (approximately 0.44), achieving a 5-year average of 0.79 (SD 0.23) as of 2019 and approaching the benchmark for well-documented reports (0.80). However, the contributing factors to this relatively high report completeness score remain unexplored.

Objective: This study aims to explore the main drivers influencing the completeness of Malaysian AE reports in VigiBase over a 15-year period using vigiGrade. A secondary objective was to understand the strategic measures taken by the Malaysian authorities leading to enhanced report completeness across different time frames.

Methods: We analyzed 132,738 Malaysian reports (2005-2019) recorded in VigiBase up to February 2021 split into historical International Drug Information System (INTDIS; n=63,943, 48.17% in 2005-2016) and newer E2B (n=68,795, 51.83% in 2015-2019) format subsets. For machine learning analyses, we performed a 2-stage feature selection followed by a random forest classifier to identify the top features predicting well-documented reports. We subsequently applied tree Shapley additive explanations to examine the magnitude, prevalence, and direction of feature effects. In addition, we conducted time-series analyses to evaluate chronological trends and potential influences of key interventions on reporting quality.

Results: Among the analyzed reports, 42.84% (56,877/132,738) were well documented, with an increase of 65.37% (53,929/82,497) since 2015. Over two-thirds (46,186/68,795, 67.14%) of the Malaysian E2B reports were well documented compared to INTDIS reports at 16.72% (10,691/63,943). For INTDIS reports, higher pharmacovigilance center staffing was the primary feature positively associated with being well documented. In recent E2B reports, the top positive features included reaction abated upon drug dechallenge, reaction onset or drug use duration of <1 week, dosing interval of <1 day, reports from public specialist hospitals, reports by pharmacists, and reaction duration between 1 and 6 days. In contrast, reports from product registration holders and other health care professionals and reactions involving product substitution issues negatively affected the quality of E2B reports. Multifaceted strategies and interventions comprising policy changes, continuity of education, and human resource development laid the groundwork for AE reporting in Malaysia, whereas advancements in technological infrastructure, pharmacovigilance databases, and reporting tools concurred with increases in both the quantity and quality of AE reports.

Conclusions: Through interpretable machine learning and time-series analyses, this study identified key features that positively or negatively influence the completeness of Malaysian AE reports and unveiled how Malaysia has developed its pharmacovigilance capacity via multifaceted strategies and interventions. These findings will guide future work in enhancing pharmacovigilance and public health.

Citing Articles

Empowering Patient Safety: Assessment of Adverse Drug Reaction Knowledge and Practice Among Pharmacy Professionals.

Bukic J, Leskur D, Durdov T, Bozic J, Modun D, Seselja Perisin A Pharmacy (Basel). 2025; 13(1.

PMID: 39846624 PMC: 11755484. DOI: 10.3390/pharmacy13010001.

References
1.
Thorsen-Meyer H, Nielsen A, Nielsen A, Kaas-Hansen B, Toft P, Schierbeck J . Dynamic and explainable machine learning prediction of mortality in patients in the intensive care unit: a retrospective study of high-frequency data in electronic patient records. Lancet Digit Health. 2020; 2(4):e179-e191. DOI: 10.1016/S2589-7500(20)30018-2. View

2.
Rolfes L, van Hunsel F, van der Linden L, Taxis K, van Puijenbroek E . The Quality of Clinical Information in Adverse Drug Reaction Reports by Patients and Healthcare Professionals: A Retrospective Comparative Analysis. Drug Saf. 2017; 40(7):607-614. PMC: 5488139. DOI: 10.1007/s40264-017-0530-5. View

3.
Ribeiro A, Lima S, Zampieri M, Peinado M, Figueras A . Filling quality of the reports of adverse drug reactions received at the Pharmacovigilance Centre of São Paulo (Brazil): missing information hinders the analysis of suspected associations. Expert Opin Drug Saf. 2017; 16(12):1329-1334. DOI: 10.1080/14740338.2017.1369525. View

4.
Ampadu H, Hoekman J, Arhinful D, Amoama-Dapaah M, Leufkens H, Dodoo A . Organizational capacities of national pharmacovigilance centres in Africa: assessment of resource elements associated with successful and unsuccessful pharmacovigilance experiences. Global Health. 2018; 14(1):109. PMC: 6240224. DOI: 10.1186/s12992-018-0431-0. View

5.
Stevens L, Mortazavi B, Deo R, Curtis L, Kao D . Recommendations for Reporting Machine Learning Analyses in Clinical Research. Circ Cardiovasc Qual Outcomes. 2020; 13(10):e006556. PMC: 8320533. DOI: 10.1161/CIRCOUTCOMES.120.006556. View